PCMA issues statement on a provision in the U.S. Senate's small business legislation

NewsGuard 100/100 Score

Pharmaceutical Care Management Association (PCMA) President and CEO Mark Merritt issued the following statement today on a provision in the U.S. Senate's small business legislation that would require the Department of Health and Human Services (HHS) to work with outside companies to target fraud, waste, and abuse in states across the country:

“Along with these initiatives, policymakers must reject policies that inadvertently weaken the ability of public and private payers to detect and prevent fraud, waste, and abuse. It's far easier to prevent fraud than to engage in 'pay and chase' activities after the fact.”

"Following the passage of health reform, an increased emphasis on overall program integrity and safeguarding taxpayer money is more important than ever. Focusing on preventing fraud, waste, and abuse is integral to these efforts.

"Along with these initiatives, policymakers must reject policies that inadvertently weaken the ability of public and private payers to detect and prevent fraud, waste, and abuse. It's far easier to prevent fraud than to engage in 'pay and chase' activities after the fact."

SOURCE Pharmaceutical Care Management Association

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
MD Anderson acquires cell therapy safety technology from Bellicum Pharmaceuticals